Cancer treatment in the coronavirus disease pandemic
- PMID: 33373838
- PMCID: PMC7832712
- DOI: 10.1016/j.lungcan.2020.12.012
Cancer treatment in the coronavirus disease pandemic
Abstract
Half a year after its emergence, severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has resulted in a pandemic, with cases continuing to increase in nearly every country. Surges in coronavirus disease of 2019 (COVID-19) cases have clearly had profound effects on current cancer treatment paradigms. Considering the effect of antineoplastic treatment and the immunosuppressive properties of cancer itself, cancer patients are deemed to be more vulnerable to SARS-CoV-2. Hence, the specific risk of SARS-CoV-2 must be carefully weighed against the benefit of antineoplastic treatment for cancer patients in the COVID-19 era. In this review, we discuss the current evidence in this important field, and in particular, the effect of SARS-CoV-2 on antineoplastic treatment.
Keywords: Antineoplastic treatment; COVID-19; Cancer; Mortality.
Copyright © 2020 Elsevier B.V. All rights reserved.
Conflict of interest statement
The authors have nothing to disclose.
Figures
References
-
- COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.
-
- Zhang L., Jackson C.B., Mou H., et al. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv. 2020 doi: 10.1101/2020.06.12.148726. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
